肿瘤药学2019，Vol.9Issue(3)：432-436,5.DOI:10.3969/j.issn.2095-1264.2019.03.17
多西紫杉醇联合表柔比星序贯化疗对局部进展期乳腺癌的临床疗效观察★
Clinical Efficacy of Sequential Chemotherapy of Docetaxel Combined with Epirubicin for Locally Advanced Breast Cancer ★
摘要
Abstract
Objective To compare the clinical efficacy, adverse reactions and MRI evaluation of neoadjuvant chemotherapy regimen do-cetaxel combined with epirubicin in sequential chemotherapy for locally advanced breast cancer. Methods A total of 120 patients with locally advanced breast cancer admitted to our hospital from January 2014 to January 2018 were selected and divided into two groups according to the random number table method. Each group included 60 cases. The control group was treated with epirubicin+ docetaxel +cyclophosphamide chemotherapy for four treatment cycles. The observation group was treated with epirubicin + cyclophosphamide as the control group during the first four cycles, but got docetaxel sequential therapy from the fifth treatment cycle. All patients were treated for 8 consecutive cycles. After treatment, evaluate and compare the clinical efficacy, adverse reactions and MRI evaluation. Results Compared with the control group, the total clinical effective rate of the observation group was significantly higher than that of the control group, and there was a significant difference be-tween the two groups (41.7% vs.66.7%, P<0.05). After treatment, the incidence of erythrocytopenia, liver function injury and constipation in the observation group were significantly lower than in the control group, while the incidence of neutropenia of observation group were significantly higher than that of the control group (P<0.05). There were no significant differences between the two groups in the incidences of leukopenia, thrombocytopenia, renal function injury and constipation (P>0.05). Nausea and vomiting occurred in both groups, and the incidence was 100% in each group. MRI evaluation results showed that the diagnostic efficiency of the observation group was significantly higher than that of the con-trol group (P<0.05). Conclusion For locally advanced breast cancer, sequential chemotherapy with docetaxel and epirubicin not only has better clinical efficacy, but also does not increase the incidence of adverse drug reactions. It has a good safety and tolerance.关键词
局部进展期/乳腺癌/多西紫杉醇/表柔比星/序贯化疗Key words
Local progression/Breast cancer/Docetaxel/Epirubicin/Sequential chemotherapy分类
医药卫生引用本文复制引用
邵华,姜磊,张华,李白艳,王媛媛..多西紫杉醇联合表柔比星序贯化疗对局部进展期乳腺癌的临床疗效观察★[J].肿瘤药学,2019,9(3):432-436,5.基金项目
新疆维吾尔自治区自然科学基金项目(2015211C097). （2015211C097）
